Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing

By sjmartinez • September 22, 2024

Lee JM. Neoadjuvant, perioperative, or adjuvant immunotherapy in resectable non-small cell lung cancer: How do I choose? Importance of immune biomarkers and molecular testing. J Thorac Cardiovasc Surg. 2024 Oct;168(4):1281-1288. doi: 10.1016/j.jtcvs.2024.03.034. Epub 2024 Apr 20. PMID: 38649111.

Tags: Adjuvant, immunotherapy, Lung cancer, neoadjuvant, NSCLC, Perioperative, Publications, Pulmonary, Critical Care & Sleep Medicine

Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

Zanni MV, Umbleja T, Fichtenbaum CJ, Fitch KV, McCallum S, Aberg JA, Overton ET, Malvestutto CD, Bloomfield GS, Currier JS, Schnittman SR, Erlandson KM, Diggs[...]

Social genomics, cognition, and well-being during the COVID-19 pandemic

Bateman JR, Krishnamurthy S, Quillen EE, Waugh CE, Kershaw KN, Lockhart SN, Hughes TM, Seeman TE, Cole SW, Craft S. Social genomics, cognition, and well-being[...]

Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT

Finn RS, Qin S, Piscaglia F, Evans TRJ, Knox JJ, López López C, Ramji Z, Ren M, Mody K, Vogel A, Kudo M. Characterization of[...]